Zhongshan-based biopharma company Akeso's independently developed tri-specific antibody drug AK150 has received implied clinical trial approval from the Center for Drug Evaluation, NMPA, enabling trials for advanced solid tumors. 

This marks the world's only ILT2/ILT4/CSF1R tri-specific antibody in development and Akeso's first tri-specific antibody drug to enter clinical testing.

AK150 demonstrates synergistic anti-tumor effects by modulating both innate and adaptive immune systems, potentially revolutionizing tumor immunotherapy efficacy. 

Notably, Akeso remains the only global pharmaceutical company with two approved bispecific immuno-oncology drugs: PD-1/CTLA-4 bispecific CADONILIMAB and PD-1/VEGF bispecific IVONESCIMAB.